Gujarat Themis Biosyn (GUJTHEM) — Financial Results

Investor Takeaways

Reported FY2026 revenue of ₹16,825.09 crores and profit after tax of ₹4,668.15 crores

Declared final dividend of ₹0.67 per share

Retained earnings increased to ₹27,671.44 crores

⚠️ No specific risks identified in this filing

Overall Tone: Positive based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹16,825.09 Cr	N/A
Net Profit	₹4,668.15 Cr	N/A
EBITDA	Not available	N/A
EPS	Not available	N/A
OPM	Not available	N/A

What Changed

Gujarat Themis Biosyn Limited reported audited FY2026 financial results showing revenue of ₹16,825.09 crores and profit after tax of ₹4,668.15 crores. The company’s retained earnings grew to ₹27,671.44 crores, reflecting cumulative profitability. Total assets were recorded at ₹50,342.66 crores, with equity at ₹28,776.78 crores. Cash flow from operations reached ₹4,877.73 crores, supporting capital expenditures and debt servicing. The final dividend of ₹0.67 per share was declared, and the financials were approved by shareholders at the upcoming AGM. The auditor confirmed compliance with Ind AS and SEBI regulations, and no material uncertainties or fraud were noted. The company maintains adequate internal controls, and the financials were filed with NSE following shareholder approval.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Gujarat Themis Biosyn Limited (GUJTHEM)	84.43	Not available	Not available	4,034.98
Sun Pharmaceutical Industries Limited (SUNPHARMA)	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited (DIVISLAB)	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited (TORNTPHARM)	80.06	N/A	N/A	1,49,108.91

The company’s P/E ratio of 84.43 is significantly higher than Sun Pharmaceutical (41.28) and Divi's Laboratories (72.41), indicating market expectations of future growth. However, peer companies report ROE and ROCE figures, while Gujarat Themis Biosyn’s ROE and ROCE are not available in the provided data.

Risks & Concerns

No specific risks identified in this filing

Quarterly Trend

[Not available in provided data. Quarterly trend section omitted.]

📄 View Original Announcement (PDF)

📊 Stock Analysis — GUJTHEM ✨ Ask AI About This

About Gujarat Themis Biosyn Limited (GUJTHEM)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹4,604.87 Cr

View full GUJTHEM stock details →

📡 Get AI alerts when GUJTHEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GUJTHEM — Free

💡 Ask AI about this filing

"What is the company's revenue growth rate YoY?" "How does the current dividend yield compare to peers?" "What is the breakdown of long-term borrowings?"

Ask AI Free →

📊 More GUJTHEM filings

See all GUJTHEM filings →

🔥 Also filed on 25 August 2026

EPL EPL Limited Annual Report AMANTA Amanta Healthcare Limited Annual Report ZEEL Zee Entertainment Enterprises Limited Annual Report FINKURVE Finkurve Financial Services Limited Corporate Action EPL EPL Limited Annual Report ARVIND Arvind Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GUJTHEM files new disclosures

Track GUJTHEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.